Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CeTMAd in Diabetic Patients with Critical Limb Ischemia
NCT01257776Phase 2Completed
- Start
- Dec 2010
- Primary completion
- Feb 2013
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous adipose-derived mesenchymal stromal cells in critical limb ischemia (CLI) (3 arms). Primary endpoints: Angiographic assessment of neovasculogenesis at 6 months and Major adverse event at 12 months. Started Dec 2010; status: completed.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT01257776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01257776.